Before it came under scrutiny by prosecutors and investors , Valeant was one of the most popular health care stocks on Wall Street . Now the drugmaker ' s relationship with Philidor and a network of affiliated pharmacies across the United States is at the heart of questions about its operations and practices . The Laval , Quebec based company has lost almost 10 billion in market value since a Wall Street short seller on Oct . 21 suggested it was using Philidor to artificially pump up retail sales and engage in Enron style accounting tactics . Valeant has denied the allegations .
